These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 3740093)

  • 1. Increased pulmonary artery pressure in association with Raynaud's phenomenon.
    Ohar JM; Robichaud AM; Fowler AA; Glauser FL
    Am J Med; 1986 Aug; 81(2):361-2. PubMed ID: 3740093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Scleroderma, pulmonary hypertension and Raynaud's syndrome].
    Duclós F; Bohórquez A; Zambrano A; Armenta J
    Rev Esp Cardiol; 1968 Apr; 21(2):223-33. PubMed ID: 5739705
    [No Abstract]   [Full Text] [Related]  

  • 3. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma).
    Salerni R; Rodnan GP; Leon DF; Shaver JA
    Ann Intern Med; 1977 Apr; 86(4):394-9. PubMed ID: 848800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary hypertension in the CREST syndrome: variant of systemic sclerosis (scleroderma)--a case report.
    Lie JT
    Angiology; 1989 Aug; 40(8):764-7. PubMed ID: 2757266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary vascular response during Raynaud's phenomenon in progressive systemic sclerosis.
    Shuck JW; Oetgen WJ; Tesar JT
    Am J Med; 1985 Feb; 78(2):221-7. PubMed ID: 3970048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raynaud's phenomenon with incomplete features of scleroderma: a wolf in sheep's clothing and a possible new indication for pulmonary/heart graft.
    Vayssairat M; Gouny P; Nussaume O
    Dermatology; 1994; 188(1):80. PubMed ID: 8305768
    [No Abstract]   [Full Text] [Related]  

  • 7. Nifedipine in pulmonary arterial hypertension. Importance of Raynaud's phenomenon.
    Fisher J; Mack RJ; Likier HM; Schiff AN; Borer JS
    Chest; 1987 Sep; 92(3):400-5. PubMed ID: 3622018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term effects of sildenafil in a patient with scleroderma-associated pulmonary hypertension and Raynaud's syndrome].
    Rosenkranz S; Caglayan E; Diet F; Karasch T; Weihrauch J; Wassermann K; Erdmann E
    Dtsch Med Wochenschr; 2004 Aug; 129(33):1736-40. PubMed ID: 15295684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paroxysmal dysarthria and Raynaud's phenomenon in the tongue.
    Nielsen HV; Kristensen JK; Klemp P; Staberg B; Thomsen K
    Acta Med Scand; 1984; 216(4):431-2. PubMed ID: 6516913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis.
    Stupi AM; Steen VD; Owens GR; Barnes EL; Rodnan GP; Medsger TA
    Arthritis Rheum; 1986 Apr; 29(4):515-24. PubMed ID: 3707629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case report. Two cases of pulmonary hypertension with Raynaud's phenomenon. Primary pulmonary hypertension and systemic lupus erythematosus.
    Kanemoto N; Gonda N; Katsu M; Fukuda J
    Jpn Heart J; 1975 May; 16(3):354-60. PubMed ID: 1160186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scleroderma and Raynaud's phenomenon.
    BARNETT AJ
    Clin Rep; 1959; 9():33-74. PubMed ID: 13796900
    [No Abstract]   [Full Text] [Related]  

  • 14. Raynaud's phenomenon and systemic sclerosis.
    Generini S; Kahaleh B; Matucci-Cerinic M; Pignone A; Lombardi A; Ohtsuka T
    Ann Ital Med Int; 1996; 11(2):125-31. PubMed ID: 8974438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
    Surwit RS; Gilgor RS; Allen LM; Duvic M
    Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis.
    O'Reilly D; Taylor L; el-Hadidy K; Jayson MI
    Ann Rheum Dis; 1992 Nov; 51(11):1193-6. PubMed ID: 1466594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raynaud's phenomenon in limited cutaneous systemic sclerosis.
    Bonnecaze AK
    BMJ Case Rep; 2015 Dec; 2015():. PubMed ID: 26715139
    [No Abstract]   [Full Text] [Related]  

  • 19. Raynaud's phenomenon and other features of scleroderma, including pulmonary hypertension.
    Wigley FM
    Curr Opin Rheumatol; 1996 Nov; 8(6):561-8. PubMed ID: 9018460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.